Angus Liu

Scholar Rock has shed Novo Nordisk's troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy.

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to secure a decisive clinical win to enter the U.S. market.

As Alnylam's Amvuttra sales disappointed, revenue from BridgeBio's rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts' expectations.

More than four years after its CAR-T star Carvykti's initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter.

As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti. Taiho Pharmaceutical and Cullinan Therapeutics' EGFR candidate delivered a phase 3 win. WuXi AppTec won a preliminary injunction against the Defense Department's black list designation. And more.

In a historic breakthrough for targeted protein degradation, Bristol Myers Squibb has secured the

Amid growing U.S. anxiety over China's rapid rise as a biotech powerhouse, a fast regulatory pathway for early development of novel cell and gene therapies has become a recent focal point.

AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although the dual wins provided little cover for the company amid the failure of a PD-1/CTLA-4 bispecific antibody.

In the first major workforce reduction disclosed under new CEO Belén Garijo, Sanofi is laying off 229 employees from legacy Blueprint Medicines in Massachusetts as part of a post-acquisition integration.

Biokin Pharma's iza-bren, a first-in-class antibody-drug conjugate partnered with Bristol Myers Squibb, has posted another positive phase 3 readout.